31,800 Shares in AxoGen, Inc. $AXGN Bought by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. acquired a new stake in shares of AxoGen, Inc. (NASDAQ:AXGN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 31,800 shares of the medical equipment provider’s stock, valued at approximately $1,469,000. Edmond DE Rothschild Holding S.A. owned approximately 0.06% of AxoGen as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of AXGN. Lisanti Capital Growth LLC acquired a new stake in AxoGen in the 2nd quarter worth about $4,183,000. Tocqueville Asset Management L.P. acquired a new position in shares of AxoGen during the second quarter valued at approximately $8,032,000. BlackRock Inc. purchased a new position in shares of AxoGen in the second quarter valued at approximately $204,123,000. Deutsche Bank AG purchased a new position in shares of AxoGen in the second quarter valued at approximately $30,106,000. Finally, Rice Hall James & Associates LLC acquired a new stake in shares of AxoGen in the second quarter worth approximately $3,414,000. Hedge funds and other institutional investors own 80.29% of the company’s stock.

AxoGen Stock Performance

AxoGen stock opened at $46.44 on Friday. The firm has a 50 day simple moving average of $43.96 and a 200-day simple moving average of $38.88. The stock has a market cap of $2.50 billion, a price-to-earnings ratio of -68.29 and a beta of 1.11. The company has a debt-to-equity ratio of 0.07, a current ratio of 6.60 and a quick ratio of 5.04. AxoGen, Inc. has a 1-year low of $13.64 and a 1-year high of $50.66.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 EPS for the quarter, meeting the consensus estimate of $0.12. The firm had revenue of $69.73 million for the quarter, compared to analyst estimates of $67.10 million. AxoGen had a negative net margin of 13.36% and a negative return on equity of 8.90%. On average, analysts expect that AxoGen, Inc. will post -0.45 EPS for the current year.

Insider Activity

In other news, EVP Marc A. Began sold 67,500 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the completion of the transaction, the executive vice president directly owned 50,135 shares in the company, valued at approximately $2,373,390.90. This represents a 57.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Mcbride Wendell sold 13,353 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total value of $646,552.26. Following the sale, the director directly owned 107,976 shares of the company’s stock, valued at $5,228,197.92. The trade was a 11.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 95,003 shares of company stock valued at $4,482,997 in the last quarter. Insiders own 2.44% of the company’s stock.

Analyst Ratings Changes

AXGN has been the subject of several research reports. Jefferies Financial Group reiterated a “buy” rating and set a $55.00 price target on shares of AxoGen in a research report on Wednesday, July 29th. Wells Fargo & Company raised their price objective on AxoGen from $40.00 to $48.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Zacks Research raised shares of AxoGen from a “strong sell” rating to a “hold” rating in a research note on Friday, May 29th. Canaccord Genuity Group upped their target price on shares of AxoGen from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Finally, Wall Street Zen upgraded shares of AxoGen from a “hold” rating to a “buy” rating in a research report on Sunday, July 26th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, AxoGen presently has an average rating of “Moderate Buy” and a consensus price target of $51.00.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.